...
首页> 外文期刊>Biochemical Pharmacology >Stereoisomers ginsenosides-20(S)-Rg 3 and -20(R)-Rg 3 differentially induce angiogenesis through peroxisome proliferator-activated receptor-gamma
【24h】

Stereoisomers ginsenosides-20(S)-Rg 3 and -20(R)-Rg 3 differentially induce angiogenesis through peroxisome proliferator-activated receptor-gamma

机译:立体异构人参皂甙-20(S)-Rg 3和-20(R)-Rg 3通过过氧化物酶体增殖物激活的受体-γ差异诱导血管生成

获取原文
获取原文并翻译 | 示例
           

摘要

Ginsenosides are considered the major constituents that are responsible for most of the pharmacological actions of ginseng. However, some ginsenosides exist as stereoisomeric pairs, detailed and molecular exposition based on the structural differences of ginsenoside stereoisomers has not been emphasized in most studies. Here we explore the functional differences of ginsenoside Rg 3 stereoisomers on angiogenesis. In this study, we demonstrated the distinctive differential angiogenic activities of 20(S)-Rg 3 and 20(R)-Rg 3 stereoisomers. 20(S)-Rg 3 at micromolar concentration promotes human endothelial cells proliferation, migration and tube formation in vitro, as well as ex vivo endothelial sprouting. The effects induced by 20(S)-Rg 3 are significantly more potent than 20(R)-Rg 3. These effects are partially mediated through the activation of AKT/ERK-eNOS signaling pathways. Moreover, knockdown of peroxisome proliferator-activated receptor-gamma (PPARγ) by specific small interference RNA abolished the 20(S)-Rg 3-induced angiogenesis, indicating that PPARγ is responsible for mediating the angiogenic activity of Rg 3. Using reporter gene assay, the PPARγ agonist activity of 20(S)-Rg 3 has been found 10-fold higher than that of 20(R)-Rg 3. Computer modeling also revealed the differential binding is due to the chiral center of 20(S)-Rg 3 can form a critical hydrogen bond with Tyr473 of PPARγ ligand binding domain. The present study elucidated the differential angiogenic effects of Rg 3 stereoisomers by acting as agonist of PPARγ. The results shed light on the structural difference between two ginsenoside stereoisomers that can lead to significant differential physiological outcomes which should be carefully considered in the future development of ginsenoside-based therapeutics.
机译:人参皂苷被认为是人参大多数药理作用的主要成分。然而,一些人参皂苷以立体异构体对的形式存在,在大多数研究中并未强调基于人参皂苷立体异构体结构差异的详细分子展示。在这里,我们探索人参皂苷Rg 3立体异构体在血管生成上的功能差异。在这项研究中,我们证明了20(S)-Rg 3和20(R)-Rg 3立体异构体具有独特的差异性血管生成活性。微摩尔浓度的20(S)-Rg 3促进人内皮细胞的体外增殖,迁移和管形成以及离体内皮发芽。由20(S)-Rg 3诱导的作用比20(R)-Rg 3显着更有效。这些作用部分是通过AKT / ERK-eNOS信号通路的激活介导的。此外,通过特异性小干扰RNA敲低过氧化物酶体增殖物激活受体-γ(PPARγ)消除了20(S)-Rg 3诱导的血管生成,表明PPARγ负责介导Rg 3的血管生成活性。 ,发现20(S)-Rg 3的PPARγ激动剂活性比20(R)-Rg 3的PPARγ激动剂活性高10倍。计算机模型还显示差异结合是由于20(S)-Rg 3的手性中心Rg 3可与PPARγ配体结合结构域的Tyr473形成关键氢键。本研究通过充当PPARγ的激动剂阐明了Rg 3立体异构体的不同血管生成作用。结果揭示了两种人参皂苷立体异构体之间的结构差异,这可能导致明显的生理差异,在基于人参皂苷的疗法的未来开发中应仔细考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号